Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Cairo University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06602167CT.gov Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome | — | Recruiting | — | — | — |
NCT05756166CT.gov Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04081389CT.gov Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03599453CT.gov Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | — | Completed | — | — | — |
NCT03084536CT.gov PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery | — | Completed | — | — | — |
NCT01067989CT.gov Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01881048CT.gov Window of Opportunity Study Targeting the Inflammatory Milieu | — | Completed | — | — | — |
NCT01769625CT.gov Changes in Biomarkers Using Prostaglandin Inhibitors | — | Completed | — | — | — |
NCT01425476CT.gov Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors | — | Completed | — | — | — |
Show 17 more trialsShow fewer
NCT00135018CT.gov Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer | — | Completed | — | — | — |
NCT00305643CT.gov Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer | — | Terminated | — | — | — |
NCT02429427CT.gov European Celecoxib Trial in Primary Breast Cancer | — | Completed | — | — | — |
NCT00088972CT.gov S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women | — | Terminated | — | — | — |
NCT00665457CT.gov Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | — | Terminated | — | — | — |
NCT01695226CT.gov Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer | — | Completed | — | — | — |
NCT00101062CT.gov Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00075673CT.gov Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00525096CT.gov Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00201773CT.gov Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer | — | Completed | — | — | — |
NCT00328432CT.gov A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy | — | Completed | — | — | — |
NCT00070057CT.gov Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer | — | Completed | — | — | — |
NCT00291694CT.gov Protocol for Women at Increased Risk of Developing Breast Cancer | — | Completed | — | — | — |
NCT00045591CT.gov Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer | — | Terminated | — | — | — |
NCT00291122CT.gov An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer | — | Completed | — | — | — |
NCT00056082CT.gov Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women | — | Completed | — | — | — |
NCT00006381CT.gov Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | Cairo University | P3 | B · 60 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Celecoxib in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/celecoxib-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →